Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CWBR Stock Summary
In the News
Why Is CohBar (CWBR) Stock Up 130% Today?
CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
7 Nasdaq Stocks to Sell Before They Die
As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500.
CohBar (CWBR) Stock: 1-For-30 Reverse Split Goes Into Effect
A 1-for-30 reverse split of CohBar (CWBR) stock has gone into effect today. These are the details.
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12 - 14, 2022.
CohBar, Inc. (CWBR) CEO Joe Sarret on Q2 2022 Results - Earnings Call Transcript
CohBar, Inc. (NASDAQ:CWBR ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Jordyn Tarazi - Director of IR Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is Ryan, and I will be your conference operator for today.
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar to Present at the H.C. Wainwright Global Investment Conference
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today its virtual participation in the 2022 H.C. Wainwright Global Investment Conference.
CohBar Inc. (CWBR) CEO Joe Sarret on Q1 2022 Results - Earnings Call Transcript
CohBar Inc. (NASDAQ:CWBR ) Q1 2022 Results Conference Call May 16, 2022 5:00 PM ET Company Participants Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is John, and I will be your conference operator today.
CWBR Financial details
CWBR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -11.42 | -9.56 | -8.99 | -6.94 | -4.13 | |
Operating cash flow per share | -7.37 | -7.08 | -6.01 | -6.51 | -3.6 | |
Free cash flow per share | -7.68 | -7.19 | -6.03 | -6.51 | -3.6 | |
Cash per share | 16.13 | 8.8 | 12.92 | 11.82 | 5.43 | |
Book value per share | 13.06 | 5.7 | 11.36 | 11.54 | 5.29 | |
Tangible book value per share | 13.05 | 5.69 | 11.35 | 11.53 | 5.28 | |
Share holders equity per share | 13.06 | 5.7 | 11.36 | 11.54 | 5.29 | |
Interest debt per share | 2.53 | 2.88 | 0.93 | 0.2 | 0 | |
Market cap | 128.29M | 68.5M | 65.41M | 23.31M | 4.93M | |
Enterprise value | 125.48M | 59.29M | 63.21M | 18.68M | -1M | |
P/E ratio | -8.17 | -5.02 | -4.47 | -1.51 | -0.41 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -12.66 | -6.78 | -6.69 | -1.61 | -0.47 | |
PFCF ratio | -12.16 | -6.68 | -6.67 | -1.61 | -0.47 | |
P/B Ratio | 7.14 | 8.42 | 3.54 | 0.91 | 0.32 | |
PTB ratio | 7.14 | 8.42 | 3.54 | 0.91 | 0.32 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -8.28 | -4.82 | -4.09 | -1.21 | 0.08 | |
EV to operating cash flow | -12.39 | -5.87 | -6.46 | -1.29 | 0.1 | |
EV to free cash flow | -11.89 | -5.78 | -6.45 | -1.29 | 0.1 | |
Earnings yield | -0.12 | -0.2 | -0.22 | -0.66 | -2.43 | |
Free cash flow yield | -0.08 | -0.15 | -0.15 | -0.62 | -2.12 | |
Debt to equity | 0.16 | 0.41 | 0.04 | 0.01 | 0 | |
Debt to assets | 0.13 | 0.25 | 0.03 | 0.01 | 0 | |
Net debt to EBITDA | 0.19 | 0.75 | 0.14 | 0.3 | 0.49 | |
Current ratio | 10.38 | 6.34 | 6.98 | 15.96 | 15.69 | |
Interest coverage | -27.52 | -16.73 | -16.18 | -210.5 | -1.21K | |
Income quality | 0.65 | 0.77 | 0.6 | 0.93 | 0.86 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | 0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -5.35 | -1.01 | -0.17 | -0.06 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 57.94 | 35.03 | 47.95 | 42.44 | 22.17 | |
ROIC | -0.75 | -1.15 | -0.62 | -0.59 | -0.79 | |
Return on tangible assets | -0.68 | -1.01 | -0.67 | -0.56 | -0.73 | |
Graham Net | 12.44 | 5.02 | 10.81 | 6.29 | 5.08 | |
Working capital | 20.28M | 10.89M | 18.36M | 25.26M | 15.18M | |
Tangible asset value | 17.94M | 8.12M | 18.47M | 25.59M | 15.31M | |
Net current asset value | 17.36M | 7.53M | 18.01M | 25.26M | 15.18M | |
Invested capital | 0.16 | 0.41 | 0.04 | 0.01 | 0 | |
Average receivables | 0 | 0 | 0 | 86.75K | 100.5K | |
Average payables | 817.38K | 793.76K | 586.19K | 549.8K | 276.05K | |
Average inventory | 0 | 0 | 0 | -10.71M | -10.71M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.87 | -1.68 | -0.79 | -0.6 | -0.78 | |
Capex per share | -0.31 | -0.1 | -0.02 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.93 | -0.8 | -1.27 | -0.7 | -1.49 | |
Operating cash flow per share | -1.18 | -0.62 | -0.94 | -0.56 | -0.62 | |
Free cash flow per share | -1.18 | -0.62 | -0.94 | -0.56 | -0.62 | |
Cash per share | 6.93 | 6.32 | 5.43 | 4.88 | 4.24 | |
Book value per share | 7.15 | 6.46 | 5.29 | 4.68 | 3.27 | |
Tangible book value per share | 7.14 | 6.45 | 5.28 | 4.67 | 3.26 | |
Share holders equity per share | 7.15 | 6.46 | 5.29 | 4.68 | 3.27 | |
Interest debt per share | 0.01 | 0.03 | 0.04 | -0.05 | 0 | |
Market cap | 16.52M | 8.36M | 4.93M | 5.17M | 8.11M | |
Enterprise value | 13.64M | 4.15M | -1M | -224.66K | 1.92M | |
P/E ratio | -1.53 | -0.9 | -0.34 | -0.64 | -0.47 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -4.84 | -4.67 | -1.81 | -3.17 | -4.5 | |
PFCF ratio | -4.84 | -4.67 | -1.81 | -3.17 | -4.5 | |
P/B Ratio | 0.8 | 0.45 | 0.32 | 0.38 | 0.85 | |
PTB ratio | 0.8 | 0.45 | 0.32 | 0.38 | 0.85 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -5.07 | -1.75 | 0.26 | 0.11 | -0.44 | |
EV to operating cash flow | -4 | -2.32 | 0.37 | 0.14 | -1.06 | |
EV to free cash flow | -4 | -2.32 | 0.37 | 0.14 | -1.06 | |
Earnings yield | -0.16 | -0.28 | -0.74 | -0.39 | -0.53 | |
Free cash flow yield | -0.21 | -0.21 | -0.55 | -0.32 | -0.22 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 1.07 | 1.78 | 1.57 | 2.56 | 1.43 | |
Current ratio | 28.45 | 34.81 | 15.69 | 15.94 | 4.16 | |
Interest coverage | -146.59 | -31.31 | -31.13 | 17.14 | 0 | |
Income quality | 1.25 | 0.75 | 0.72 | 0.75 | 0.42 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 12.25 | 10.76 | 12.27 | 8.61 | 10.47 | |
ROIC | -0.13 | -0.13 | -0.25 | -0.16 | -0.48 | |
Return on tangible assets | -0.13 | -0.12 | -0.22 | -0.14 | -0.35 | |
Graham Net | 6.68 | 6.13 | 5.08 | 4.57 | 3.21 | |
Working capital | 20.42M | 18.48M | 15.18M | 13.42M | 9.47M | |
Tangible asset value | 20.69M | 18.73M | 15.31M | 13.49M | 9.49M | |
Net current asset value | 20.42M | 18.48M | 15.18M | 13.42M | 9.47M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 13.75K | 13.75K | 21.16K | |
Average payables | 474.65K | 282.96K | 218.71K | 356.26K | 954.08K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.13 | -0.12 | -0.24 | -0.15 | -0.46 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CWBR Frequently Asked Questions
What is CohBar, Inc. stock symbol ?
CohBar, Inc. is a US stock , located in Menlo park of Ca and trading under the symbol CWBR
What is CohBar, Inc. stock quote today ?
CohBar, Inc. stock price is $0.8801 today.
Is CohBar, Inc. stock public?
Yes, CohBar, Inc. is a publicly traded company.